Suzanne Nguyen

Learn More
PURPOSE To compare epirubicin, cisplatin, and capecitabine (ECX) with fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatments in patients with advanced gastric or esophagogastric junction (EGJ) adenocarcinoma. PATIENTS AND METHODS This open, randomized, phase III study was carried out in 71 centers. Patients with locally advanced or(More)
BACKGROUND The purpose of this study was to evaluate the combination of panitumumab and irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy (oxaliplatin, fluoropyrimidines-irinotecan and bevacizumab). PATIENTS AND METHODS KRAS status was first determined locally but subsequent validation of KRAS(More)
METHODS We evaluated the Epitax combination (epirubicin 60 mg/m2 and docetaxel 75 mg/m2, every 3 weeks) in advanced gastric cancer (AGC) as second-line treatment after fluorouracil and platinum in 50 patients, then as first-line treatment in 36 patients. We report here the results of these two phase II studies. RESULTS In the second-line treatment, the(More)
PURPOSE GemOx was defined as a D1-D2 schedule, based on preclinical data. In order to improve convenience for patients, we evaluated a simplified D1-D1 GemOx regimen (S-GemOx) in MPA. PATIENTS AND METHODS Patients (pts) with MPA were 2:1 randomly assigned for first-line treatment to S-GemOx (gemcitabine 1,000 mg/m(2), 100-minute infusion D1 immediately(More)
4062 Background: Epirubicin and docetaxel (Epitax) are active as second-line treatment of patients with advanced gastric cancer resistant to cisplatin-based combination (Louvet et al, ASCO 1999). This multicentric phase II study was performed to evaluate the efficacy and safety of this combination in chemo-naive patients with locally advanced (LA) or(More)
BACKGROUND For resectable gastric cancer, both postoperative chemoradiotherapy and perioperative chemotherapy demonstrate high-level evidence for improved survival in Western populations. To evaluate the feasibility of pre- or postoperative chemoradiotherapy, we proposed two multicentre phase II studies. PATIENTS AND METHODS Patients with localised,(More)
4108 Background: In locally advanced gastric cancer, perioperative chemotherapy (CT) is often recommended. The chemoradiotherapy (CTRT) interest is supported by the high risk of regional recurrence. The aim of this trial was to assess the feasibility of complete treatment (CT+CTRT+surgery) with a CT regimen efficient and well tolerated in metastatic phase.(More)
  • 1